A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.

Sarah L P Atkins,Yoshimi Endo Greer,Sarah Jenkins,Margaret E Gatti-Mays,Nicole Houston,Sunmin Lee,Min-Jung Lee, Shraddha Rastogi,Nahoko Sato, Christina Burks,Christina M Annunziata,Jung-Min Lee,Kunio Nagashima,Jane B Trepel,Stanley Lipkowitz,Alexandra S Zimmer

ONCOLOGIST（2023）

引用 0|浏览2

暂无评分

摘要

ONC201 monotherapy did not induce objective responses in recurrent or refractory metastatic breast or endometrial cancer at the RP2D dose of 625 mg weekly but had an acceptable safety profile (ClinicalTrials.gov Identifier: NCT03394027).

查看译文

关键词

ONC201,breast cancer,endometrial cancer,phase II,clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要